NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

ABSTRACT: The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab therapy by mediating antibody-dependent cellular cytotoxicity via their FcγRIII receptor (CD16), but they are also rapidly decreased following initiation of daratumumab treatment. We characterized the NK cell phenotype at baseline and during daratumumab monotherapy by flow cytometry and cytometry by time of flight to assess its impact on response and development of resistance (DARA-ATRA study; NCT02751255). At baseline, nonresponding patients had a significantly lower proportion of CD16⁺ and granzyme B⁺ NK cells, and higher frequency of TIM-3⁺ and HLA-DR⁺ NK cells, consistent with a more activat

SUBMITTER: Verkleij CPM 

PROVIDER: S-EPMC10155898 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature